Biomarkers for systemic lupus erythematosus: an update

Kim, Hyoun‐Ah; Jung, Ju‐Yang; Suh, Chang‐Hee

doi:10.2217/ijr.15.17

Cited by 3 publications

(2 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The characterization of metabolic alterations might be useful in the discovery of new biomarkers to improve the early diagnosis of these diseases, the classification of patients, the prediction of response to specific therapies, and treatment personalization [ 27 ]. Biomarkers proposed through metabolomics can be physiopathologically relevant molecules involved in the development of the disease, since their alterations may occur during immune cell activation [ 28 , 29 ]. The area of immunometabolism explains how the alterations of immune function relate to changes in intracellular metabolic pathways.…”

Section: Metabolomicsmentioning

confidence: 99%

Metabolites and metabolic pathways associated with rheumatoid arthritis and systemic lupus erythematosus

Duarte-Delgado

Cala

Barreto

et al. 2022

Journal of Translational Autoimmunity

View full text Add to dashboard Cite

Section: Metabolomicsmentioning

confidence: 99%

Metabolites and metabolic pathways associated with rheumatoid arthritis and systemic lupus erythematosus

Duarte-Delgado

Cala

Barreto

et al. 2022

Journal of Translational Autoimmunity

View full text Add to dashboard Cite

“…SLE is a chronic inflammatory disease characterized by heterogeneous clinical manifestations and immunological abnormalities, especially the overproduction of autoantibodies, primarily to the nuclear materials of the cell, complement activation, and the deposition of the circulating immune complexes (CIC) in various tissues leads to inflammatory [7][8][9]. Multiple mechanisms may be participated in the pathophysiology of SLE, comprising incomplete clearance of apoptotic and necrotic materials, abnormal exposure to autoantigens, hyperactivity of self-reactive B and T lymphocytes, and increased levels of B-cell stimulatory cytokines [10][11][12]. Interferon regulatory factor-5 (IRF5) is a protein that is in humans encoded by IRF5 gene [13].…”

Section: Introductionmentioning

confidence: 99%

Correlation Between Gene Expression of Interferon Regulatory Factor-5 and Disease Activity Index in Systemic Lupus Erythematosus Iraqi Patients

Dahham

Haddad²

2023

Iraqi Journal of Science

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by elevated levels of circulating anti-nuclear autoantibodies and interferon-alpha (INFs-α). Interferon regulatory factor-5 (IRF5) plays an important role in the induction of type I interferon and pro-inflammatory cytokines, and participates in the SLE pathogenesis. This study aimed to investigate the role of IRF5 gene expression levels in a sample of SLE Iraqi patients and its correlation with disease activity, and to identify its diagnostic ability as a biomarker reflecting disease activity. Blood samples were taken from 45 participants diagnosed with SLE cases classified according to the American College of Rheumatology (ACR) criteria. They were scored via the SLE disease activity index 2000 (SLEDAI-2K) to assess the disease activity and according to it, they were subdivided into “SLE (I) group” (SLEDAI-2k ≤5), and “SLE (II) group” (SLEDAI-2k >5), as well as age and gender matched healthy control group. RNA was isolated from whole blood samples and gene expression levels of IRF5 were determined using real-time polymerase chain reaction (PCR). Our results revealed that the expression levels of the IRF5 gene were significantly increased in SLE (I) and SLE (II) patient groups compared with the control group (p<0.05, and p<0.01) respectively, as well as higher in SLE (II) group than the SLE (I) group (p<0.01). Moreover, the expression levels of IRF5 were found to be related positively and significantly to the disease activity index in both SLE patient groups. The analysis of receiver operator curves (ROC) for gene expression levels of IRF5 in SLE (II) group showed a perfect accuracy to distinguish between SLE patients and healthy individuals (AUC=0.989, sensitivity= 95.5%, and specificity= 88.0%). However, in SLE (I) group showed a good accuracy to discriminate between SLE patients and healthy individuals. (AUC=0.769, sensitivity= 69.6%, and specificity= 80.0%). The correlation between gene expression levels of IRF5 with other parameters revealed that a significant positive correlation was found with uric acid and ALP in SLE (I) group, while in SLE (II) group with urea, creatinine, and uric acid. Our conclusion suggests that the up-regulation of IRF5 gene expression levels correlates positively with disease activity in SLE patients reflecting the possibility of using it as an immunological biomarker for diagnosis, and monitoring the disease flare.

show abstract

Evaluation of potential biomarkers for the diagnosis and monitoring of Systemic Lupus Erythematosus using the Cytometric Beads Array (CBA)

Alves

Carvalho

Nunes

et al. 2019

Clinica Chimica Acta

View full text Add to dashboard Cite

Biomarkers for systemic lupus erythematosus: an update

Cited by 3 publications

References 78 publications

Metabolites and metabolic pathways associated with rheumatoid arthritis and systemic lupus erythematosus

Metabolites and metabolic pathways associated with rheumatoid arthritis and systemic lupus erythematosus

Correlation Between Gene Expression of Interferon Regulatory Factor-5 and Disease Activity Index in Systemic Lupus Erythematosus Iraqi Patients

Evaluation of potential biomarkers for the diagnosis and monitoring of Systemic Lupus Erythematosus using the Cytometric Beads Array (CBA)

Contact Info

Product

Resources

About